MYBPC3 hypertrophic cardiomyopathy can be detected by using advanced ECG in children and young adults

E Fernlund1, P Liuba2, J Carlson3

  • 1Department of Pediatric Cardiology, Pediatric Heart Center, Skane University Hospital and Lund University; Department of Pediatrics, Linkoping University Hospital, Linkoping University, Sweden.

Insights

An advanced 12-lead ECG score significantly improves detection of hypertrophic cardiomyopathy (HCM) in young individuals. This new method shows greater sensitivity and specificity than conventional ECG for identifying MYBPC3-HCM.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Diagnostics

Background:

  • Conventional ECG has limitations in diagnosing hypertrophic cardiomyopathy (HCM), especially in children and athletes, with up to 25% of adults and higher percentages of children with HCM showing no distinct abnormalities.
  • A novel 5-minute resting advanced 12-lead ECG (A-ECG) score has demonstrated superiority over conventional ECG criteria in identifying adult HCM.

Purpose of the Study:

  • To evaluate the sensitivity and specificity of the A-ECG score in detecting echocardiographic HCM associated with the MYBPC3 genetic mutation in children and young adults.
  • To assess the A-ECG score's ability to differentiate individuals with MYBPC3 HCM from healthy controls and young athletes.

Main Methods:

  • A-ECG and conventional ECGs were obtained from 15 young patients (0-30 years) with MYBPC3 mutation and phenotypic HCM.
  • ECG results were compared to those of 198 healthy children and young adults (1 month-30 years) and 36 young endurance-trained athletes.

Main Results:

  • The A-ECG score increased sensitivity for detecting MYBPC3 HCM from 46% to 87% compared to conventional ECG criteria (p<0.05).
  • The A-ECG score demonstrated superior specificity in healthy controls (94% vs. 87%, p<0.01) and particularly in young athletes (100% vs. 69%, p<0.001).

Conclusions:

  • A 2-parameter 12-lead A-ECG score is significantly more sensitive and specific than conventional ECG criteria for detecting MYBPC3-HCM in children and young adults.
  • The A-ECG score effectively distinguishes patients with MYBPC3 HCM from healthy individuals, including endurance-trained athletes.
Abstract

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
652
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
738
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
605
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
783
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
402
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
709